Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 1;28(1):34-43.
doi: 10.1093/annonc/mdw413.

Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples

L A Renfro  1 , D J Sargent  1
Affiliations
Review

Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples

L A Renfro et al. Ann Oncol. .

Abstract

In recent years, cancers once viewed as relatively homogeneous in terms of organ location and treatment strategy are now better understood to be increasingly heterogeneous across biomarker and genetically defined patient subgroups. This has produced a shift toward development of biomarker-targeted agents during a time when funding for cancer research has been limited; as a result, the need for improved operational efficiency in studying many agent-and-target combinations in parallel has emerged. Platform trials, basket trials, and umbrella trials are new approaches to clinical research driven by this need for enhanced efficiency in the modern era of increasingly specific cancer subpopulations and decreased resources to study treatments for individual cancer subtypes in a traditional way. In this review, we provide an overview of these new types of clinical trial designs, including discussions of motivation for their use, recommended terminology, examples, and challenges encountered in their application.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
General schema of a master protocol.
Figure 2.
Figure 2.
General schema of a basket trial (one ‘basket’ of potentially many baskets shown).
Figure 3.
Figure 3.
General schema of an umbrella trial.
See this image and copyright information in PMC

References

    1. Chapman PB, Hauschild A, Robert C et al. . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–2516. - PMC - PubMed
    1. Slamon DJ, Leyland-Jones B, Shak S et al. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792. - PubMed
    1. Swain SM. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724–734. - PMC - PubMed
    1. Armado RG, Wolf M, Peeters M et al. . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626–1634. - PubMed
    1. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. . Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040–2048. - PubMed

Substances